Responsible to lead a cross-functional matrix organization to build an industry-leading, efficient, large-volume customer support and solution model that efficiently moves patients through an integrated delivery network by increasing Hub and Specialty Pharmacy through-put while shortening the time to paid drug dispense. Responsible for the Enrollment to RX customer service points (Hub, SP, retail and IDN points of sale as well as the strategic focus to evolve and drive the future state for the brand’s customer service and support platform.Leads the design of the optimal integrated delivery operational model and mitigate disruptive redundancies while providing first in class HCP & Patient support.Lead team to elevate and shape the product class at the practice level to where HCPs and their office staff have a robust understanding of how to appropriately navigate the payer criteria and specialty journey. Leads team to optimize distribution and account / prescriber data throughout the integrated delivery journey.

Responsible for US and Global Marketing for first in class cardiovascular product with focus on patient and provider program ensuring access and acceptability of product.

Franchise marketing lead for Prograf® (tacrolimus) and ASTAGRAF® XL (tacrolimus extended release) both indicated for solid organ transplant. Priorities included building marketing team (HCP and Consumer), establishing USA market planning and launch execution for ASTAGRAF XL, establishing pricing and ensuring market access; as well as leading brand planning and execution for Prograf. Directed the ongoing development of product portfolio for solid organ transplant, leading commercial planning and new product development. Responsible for P&L as well as long-term planning.

Promoted to Global Marketing Lead for Orencia® (abatacept) for rheumatoid arthritis patients with key objective to lead WW launch of Orencia subcutaneous formulation and tasked with developing strategy to grow brand sales from $1 billion to $2 billion. Priorities included establishing global market planning and execution for global launches, pricing, market access, leading team to successful on time approvals in Australia, Canada and Europe as well as structuring secure manufacturing supply chain. Directed the ongoing development of product portfolio for multiple development programs, leading commercial plans, revised global pricing strategy and new product development.

Global Marketing and Lifecycle Management Lead Nulojix® (belatacept) for organ transplant patients. Priorities included developing global commercial plans, revising global pricing strategy, ensuring market access, new product development and evaluation/prioritization of new disease targets for internal science and external business development in bone marrow and solid organ transplant.

Led infectious disease and oncology business from early portfolio prioritization of science and new business development opportunities through commercialization. Led the development of 6 novel early and late stage products for the treatment of solid tumors and infectious disease through phase III development. Responsible for P&L and long-term revenue planning as well as new business development evaluations in Infectious Disease, Oncology and Immunology.Led the launch of $200M+/year product into Asia. Managed co-promotion agreement with partner in Asia.Led commercial valuation and assessment for over 30 business development asset evaluations within oncology and autoimmune disorders.

Priorities including identifying new potential business partners, growing existing business and ensuring project profitability.

Responsible for pre-launch planning, market development and US launch of $250M/year polyclonal antibody. Responsible for marketing, market research, direct-to-patient and patient advocacy. Although product was fifth to market, because market share leader within 1-year post-launch in a highly competitive marketplace.